Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526498 · ClinicalTrials.gov registry record · Phase 2
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
A Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 10
- Study locations
NCT02526498: Completed Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT02526498 is a Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 200 participants, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02526498, a Phase 2 study of Invasive Breast Carcinoma and Stage IIA Breast Cancer, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes (early-stage) after surgery. Radiation therapy uses a type of energy to kill cancer cells and shrink tumors. Brachytherapy is a type of internal radiation therapy that provides radiation inside the breast to any remaining tumor cells next to the space where the tumor was removed, and is given over a shorter amount of time than standard radiation therapy. Giving accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy may reduce the overall time that radiation is delivered to the tumor cells.
Primary Outcome
Measured by the data collected for toxicity and cosmesis as dichotomous variables. This will be assessed by physical examination at each follow-up visit. To be scored as a serious toxicity counting toward the primary endpoint, the toxicity must have a "probable" or "definite" attribution to the study treatment.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- RADIATION Accelerated Partial Breast Irradiation
- RADIATION High-Dose Rate Brachytherapy
Study Locations (10)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
- 21st Centry Oncolgy - Yonkers
Arizona
- Arizona Breast Cancer - Gilbert
California
- University of California, San Diego - La Jolla
Michigan
- William Beaumont Hospital Research Institute - Royal Oak
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Bryn Mawr Hospital - Bryn Mawr
Utah
- Huntsman Cancer Hospital, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
What the finished NCT02526498 record still lists
NCT02526498 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower).
The record links to 7 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT02526498 lists 10 locations in 8 states (New Jersey, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT02526498 about?
NCT02526498 is a clinical study titled "Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery". This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes (early-stage) after surgery. Radiation therapy uses a type of en...
What is the current status of trial NCT02526498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2015-07-15. Estimated completion is 2021-03-31.
What conditions does trial NCT02526498 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02526498?
The interventions under investigation include: Questionnaire Administration (OTHER), Accelerated Partial Breast Irradiation (RADIATION), High-Dose Rate Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT02526498?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02526498 being conducted?
This trial has 10 study locations across Arizona, California, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02526498's enrollment target sits among peer trials
200 17th of 45 higher than 27 of 45 other Invasive Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Invasive Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI